Spindle cell sarcomas consist of tumors with different biological features, of which distant metastasis is the most ominous sign for a poor prognosis. However, metastasis is difficult to predict on the basis of current histopathological analyses. We have identified actin filament-associated protein 1-like 1 (AFAP1L1) as a candidate for a metastasis-predicting marker from the gene expression profiles of 65 spindle cell sarcomas. A multivariate analysis determined that AFAP1L1 was an independent factor for predicting the occurrence of distant metastasis (P ¼ 0.0001), which was further confirmed in another set of 41 tumors by a quantitative mRNA expression analysis. Immunohistochemical staining using paraffin-embedded tumor tissues revealed that the metastasis-free rate was significantly better in tumors negative for AFAP1L1 (P ¼ 0.0093 by log-rank test). Knocking down the AFAP1L1 gene in sarcoma cells resulted in inhibition of the cell invasion, and forced expression of AFAP1L1 in immortalized human mesenchymal stem cells induced anchorage-independent growth and increased cell invasiveness with high activity levels of matrix metallopeptidase. Furthermore, tumor growth in vivo was accelerated in AFAP1L1-transduced sarcoma cell lines. These results suggest that AFAP1L1 has a role in the progression of spindle cell sarcomas and is a prognostic biomarker.
Introduction
Sarcomas are non-epithelial malignant tumors that develop in mesenchymal tissue and classified into two groups on the basis of cellular morphology. Small round cell sarcomas, also known as blue tumors from their color on hematoxylin and eosin staining, include alveolar rhabdomyosarcomas and Ewing's sarcomas that develop in soft tissue and bone, respectively. Both have tumor-specific chromosomal translocations creating tumor-specific fusion genes (Helman and Meltzer, 2003; Toguchida and Nakayama, 2009) . Spindle cell sarcomas, named for their flattened, elongated and fibroblastic morphology, far outnumber the first group. Malignant fibrous histiocytomas (MFHs) and ostesarcomas, the prototypes of this second group, develop in soft tissue and bone, respectively. They are generally radio-and chemoresistant, although high-dose, multidrug combination chemotherapy is effective for osteosarcomas. Except for some tumors, such as synovial sarcomas, which are characterized as having SYT-SSX fusion genes (Clark et al., 1994) , most spindle cell sarcomas lack tumorspecific genetic alterations (Toguchida and Nakayama, 2009 ). Mutations of tumor suppressor genes such as the RB and p53 genes are found in many cases but not all (Toguchida et al., 1992; Wadayama et al., 1994) . The histopathological complexity of soft tissue sarcomas is an issue. For example, MFH used to be considered the most prevalent soft tissue sarcoma but now the pathological concept is controversial (Fletcher et al., 2001) . To overcome this complexity, a number of gene expression profiling studies have been performed to classify spindle cell sarcomas and identify prognostic markers (Nielsen et al., 2002; Lee et al., 2004; Francis et al., 2007; Nakayama et al., 2007) . Our group has also identified such markers using a custom-made cDNA microarray consisting of 23 040 genes in various types of malignant tumors (Nagayama et al., 2002) . As for synovial sarcomas, we have identified fibroblast growth factor (Ishibe et al., 2005) , Wnt-FZD10 (frizzled homolog 10) (Nagayama et al., 2005) and retinoic acid signals as molecular targets in synovial sarcomas (Ishibe et al., 2008) . For other types of tumors, however, the identification of tumor-specific markers is made difficult by small numbers of cases. Therefore, we have taken a different approach using the microarray data, trying to identify genes associated with aggressive phenotypes irrespective of the pathological diagnosis. Using distant metastasis as a discriminating factor, we have identified actin filament-associated protein 1-like 1 (AFAP1L1) as a candidate prognostic marker for spindle cell sarcomas. Here, we report that AFAP1L1 has a significant role in the progression of spindle cell sarcomas and is a prognostic marker as well as a potential target for molecular therapy.
Results
Identification of AFAP1L1 as a metastasis-related gene in spindle cell sarcomas Genome-wide gene expression profiles of 65 soft tissue spindle cell sarcomas (STSs) were analyzed with a cDNA microarray system consisting of 23 040 genes, and mesenchymal stem cells (MSCs) were used as a reference (Nagayama et al., 2002) . The expression of each gene in tumor samples was demonstrated as the ratio of the signal intensity in tumor samples and MSCs (Nagayama et al., 2002) . Tumor samples were classified as positive for the gene if the ratio was more than 1.0, and negative if the ratio was 1.0 or less. Distant metastases developed in 29 cases, the remaining 36 patients being metastasis-free until the last follow-up (minimum of 61 months). The fraction of cases positive for each gene was calculated among tumors with and without metastasis, and statistical analyses were performed to identify genes associated with distant metastasis. This procedure identified the AFAP1L1 gene, for which 21 of 29 cases with metastasis ( Figure 1a ) and 11 of 36 cases without metastasis ( Figure 1b) were positive, and the difference was statistically significant (P ¼ 0.0011, Fisher's exact test). When the 65 cases were divided into AFAP1L1 ( þ ) and AFAP1L1 (À) groups on the basis of the value relative to that of MSC, the metastasis-free fraction of AFAP1L1 ( þ ) cases was lower than that of AFAP1L1 (À) cases (Figure 1c ). AFAP1L1 is a member of the AFAP family along with AFAP-110 and AFAP1L2. AFAP-110 was identified as one of several major substrates of the viral oncogenic protein tyrosine kinase v-Src (Kanner et al., 1990; Flynn et al., 1993) and has been shown to function as an actin filament crosslinking protein with a fundamental role in the actin cytoskeleton's arrangement (Baisden et al., 2001a) . Moreover, it has been demonstrated that AFAP-110 is overexpressed in breast and prostate cancers and contributes to tumorigenic growth by regulating focal contact sites (Dorfleutner et al., 2007; Zhang et al., 2007) . No previous reports concerning the function or involvement in cancer of AFAP1L1 have been published.
Although the overall amino-acid sequence similarity between AFAP-110 and AFAP1L1 is as much as 44%, AFAP1L1 shared most of the predicated domain structures with AFAP-110, such as two pleckstrin homology domains, two Src homology 2 domains (SH2), and a putative leucine zipper domain (Figure 2a ) (Baisden et al., 2001a) . A polyclonal antibody was raised against its 79 N-terminal amino acids, which showed no homology with AFAP-110 (Figure 2a ). Western blotting using this antibody showed a band with a molecular size of 90-100 kD in cell lines expressing the AFAP1L1 gene (Figure 2b ). When a set of sarcomas and human MSCs (hMSCs) were analyzed by quantitative PCR (qPCR), clear differences in the expression patterns between AFAP-110 and AFAP1L1 were found (Figure 2c ). The expression of AFAP1L1 was much higher in sarcoma The expression level of the AFAP1L1 gene in each tumor is demonstrated relative to that in human bone marrow stem cells (hBMSCs). For convenience, the highest value is set as 100. Samples with a relative value of more than 100 are indicated by asterisks, and those with a relative value of less than 1.0, by rectangles. LMS, leiomyosarcoma; LS, liposarcoma; MFH, malignant fibrous histiocytoma; MPNST, malignant peripheral nerve sheath tumor; SS, synovial sarcoma; UDS, undifferentiated sarcoma. (c) Metastasis-free fraction of the initial set of STSs. A total of 65 STSs were divided by the expression level of the AFAP1L1 gene relative to that in hBMSCs: the relative value in AFAP1L1 ( þ ) tumors was more than 1.0 and the relative value in AFAP1L1 (À) tumors was equal to or less than 1.0. The metastasisfee fraction of each group was demonstrated by a Kaplan-Meier curve.
AFAP1L1 as a prognostic marker of sarcomas M Furu et al tissues and cell lines than in normal hMSCs (Po0.0001, Man-Whitney U test), whereas the expression of AFAP-110 was slightly higher in MSCs than in sarcoma tissues and cell lines (P ¼ 0.0122, Man-Whitney U test) (Figure 2c ). On the basis of these results, we focused on the AFAP1L1 gene.
Confirmation of the significance of AFAP1L1 in multivariate analyses
To confirm the significance of AFAP1L1 expression in the clinical behavior of STSs, the 65 cases were divided into two or more groups on the basis of clinicopathological factors, such as gender, age, location, size, depth, previous treatment history, surgery, and chemotherapy, pathological stage and pathological diagnosis, in addition to the expression of AFAP1L1 (Table 1) . These factors were known to contribute to the prognoses in sarcoma patients (Ottaiano et al., 2005) . When the occurrence of distant metastases was used as an endpoint, AFAP1L1 expression was confirmed as a significant factor along with age and FNCLCC grade in univariate analyses (Table 1) . These three factors were found to contribute independently to the prognosis in multivariate analyses (Table 1) .
Association of AFAP1L1 expression with metastasis was confirmed in the second set of tumors To confirm the significance of AFAP1L1 gene expression, a second set of tumors consisting of 41 STSs was analyzed (Supplementary Table 1 ). Their clinical characteristics were almost equivalent to those of the tumors used in the initial analyses except for the pathological classification, due to a recent refinement of the diagnostic criteria for MFH (Fletcher et al., 2002) . STSs with no definitive features, which might be diagnosed as MFHs, were classified as 'undifferentiated sarcomas' in most cases. During the follow-up period (4-210 months for all patients; 29-210 months for living patients), 18 developed distant metastases and 23 were free from metastasis until the last follow-up, and the qPCR analysis was used to evaluate the expression of the AFAP1L1 gene in tumors of each group. In all, 48 of 65 samples in the first set of tumors were available for the qPCR analysis, which showed that the expression level of the AFAP1L1 gene was significantly higher in tumors with metastasis Figure 3a ). A similar difference was found in the second set of tumors: The expression level of the AFAP1L1 gene was significantly higher in tumors with metastasis (N ¼ 23) than without metastasis (N ¼ 19) (P ¼ 0.0093, Man-Whitney U test). Therefore, the association of AFAP1L1 gene expression with metastatic activity was confirmed in the second set of STSs.
Immunohistochemical analysis of AFAP1L1 protein in sarcomas
The expression of the AFAP1L1 protein was analyzed in paraffin-embedded specimens of 36 STSs from the second set of tumors, in which AFAP1L1 had already been analyzed by qPCR. On the basis of staining intensity of positive cells, tumors were classified into four groups; negative (À, 15 cases), weakly positive ( þ , 6 cases), moderately positive ( þ þ , 10 cases), and (Figure 4b ). In positive cases, AFAP1L1 was detected predominantly in the cytoplasm of tumor cells. When tumors were simply divided into AFAP1L1-negative (À, 15 cases) and positive cases ( þ , þ þ and þ þ þ , 21 cases), the stepwise regression model showed that the metastasis-free fraction of AFAP1L1-negative cases was significantly higher than that of positive cases ( Figure 4c ). There was no significant difference between tumors positive and negative for the staining in terms of patient's age, tumor size and tumor depth. As for FNCLCC grade, however, the number of high-grade tumor (grade 3) in positive cases (12/21 cases) was significantly higher than that in negative cases (3/15 cases) (P ¼ 0.0407, Fisher's exact test). Therefore, the association of AFAP1L1 expression with metastasis was confirmed by both mRNA and protein analyses, suggesting AFAP1L1 to be a prognostic marker of spindle cell sarcomas.
Inhibition of AFAP1L1 expression reduced the invasiveness We next generated AFAP1L1-knocked down cells to investigate the function of AFAP1L1 using an RNA interference system mediated by a lentivirus. U2OS and 1273/99 cells were used in these experiments because they had abundant AFAP1L1 expression among sarcoma cell lines tested (Figure 5a ). Two non-targeting sequences for mammalian genes (control RNAi-1 and -2) and two AFAP1L1-targeting sequences (AFAP1L1 RNAi-1 and -2) were employed for further experiments. The transduction efficiency was 90-95% in U2OS cells and 85-90% in 1273/99 cells, as determined by counting EmGFP-positive cells (data not shown), and the knockdown of AFAP1L1 was confirmed effective by western blotting (Figure 5a ). As for proliferative ability, no differences were found between the AFAP1L1-knockdown cells and control cells in the U2OS (Figure 5b ) and 1273/99 cell lines (data not shown). However, matrigel invasion assays revealed that knocking down AFAP1L1 resulted in reduced cell invasiveness (Figure 5c ).
Induction of AFAP1L1 gene expression conferred invasiveness
The cells of origin for sarcomas remain unclear but one possible candidate is the MSC (Matushansky et al., 2007) , so we chose immortalized human MSCs (ihMSCs) as a recipient for AFAP1L1 transduction. ihMSCs were established in our laboratory and shown to be fully transformed when the activated H-ras gene had been AFAP1L1 as a prognostic marker of sarcomas M Furu et al introduced . pLenti6/AFAP1L1 was transduced into ihMSCs, and several clones stably expressing AFAP1L1 were established (ihMSC/AFAP1L1) and used for further experiments (Figure 6a ). The growth of AFAP1L1-transduced clones showed no significant change compared with that of the parental ihMSCs or ihMSC/ LacZ cells (data not shown), whereas invasiveness and anchorage-independent growth were exaggerated in all four ihMSC/AFAP1L1 clones (Figures 6b and c) .
Tumor invasiveness correlates with the activity of matrix metalloproteinases (MMPs), such as gelatinases, MMP-2 and MMP-9 (Egeblad and Werb, 2002; Overall and Kleifeld, 2006) . To determine whether the increased invasive ability of the ihMSC/AFAP1L1 clones was related to increased excretion of MMPs, gelatin zymography was performed. The ihMSC/AFAP1L1 clones showed significantly increased activity of MMP-9 but not MMP-2 compared with control cells (Figure 6d ). The increased excretion of MMP-9 in two ihMSC/AFAP1L1 clones was also confirmed by enzyme-linked immunosorbent assay (Figure 6e ). These results suggest that AFAP1L1 endows ihMSCs with invasiveness, at least partly, by regulating MMP-9's excretion. In clinical samples, however, the expression level of MMP-9 was not clearly associated with that of AFAP1L1 (R 2 ¼ 0.248) (Supplementary Figure S1) .
Acceleration of tumor growth by AFAP1L1 expression in vivo
The inoculation of ihMSC/AFAP1L1 clones subcutaneously into immunodeficient mice produced no tumors (data not shown), indicating that the overexpression of AFAP1L1 in immortal cells was not enough for full transformation. To investigate whether AFAP1L1 modifies the phenotype of sarcoma cells without endogenous AFAP1L1 expression in vivo, stably expressing cell lines were generated using Saos2 cells as a recipient (Saos2/AFAP1L1) ( Figure 7a ). The growth of Saos2/AFAP1L1 clones in vitro showed no significant change compared with that of parental Saos2 or Saos2/ LacZ control cells, but the invasive activity of Saos2/ AFAP1L1 clones increased, which was consistent with that of ihMSC/AFAP1L1 clones (data not shown). These Saos2 clones were subcutaneously inoculated into the back of non-obese diabetic/severe combined immunodeficient mice to evaluate tumorigenesis and metastasis. Tumor growth was accelerated in Saos2/ AFAP1L1 clones, although the extent of the increase seemed not to completely match the level of AFAP1L1 expression (Figures 7b and c) . There was no metastasis by any Saos2/AFAP1L1 clones or control cells, suggesting that the expression of AFAP1L1 was not enough to produce distant metastasis in this animal model.
Discussion
Tumor type-specific molecular markers have been searched for in a variety of malignant tumors, in order to predict biological phenotype and/or serve as a target for therapy. In the case of spindle cell sarcomas, however, the diversity and rarity of tumors have hampered such efforts. The importance of this study lies in having identified AFAP1L1 as a metastatic and a prognostic marker of spindle cell sarcomas, irrespective of pathological diagnosis. However, the significance of this gene in the development of distant metastasis should be carefully evaluated because our strategy focused on the contribution of single genes. Recently, two studies using large numbers of samples have been published relating to prognostic and therapeutic markers for soft tissue sarcomas. Barretina et al. (2010) performed an intensive analysis of 722 protein-coding and miRNA genes using a combination of DNA sequencing and a single-nucleotide polymorphism array and identified several tumor subtype-specific genetic alterations, some of which could be molecular targets for therapy. Chibon et al. (2010) identified a set of 67 genes on the basis of genomic and expression profiling and established a complexity index in sarcomas, which can predict the prognosis of patients. Among 67 genes, most were related to mitosis and chromosome management, and the AFAP1L1 gene was not included.
Clinical results clearly demonstrated the association of AFAP1L1 with metastatic behavior of sarcomas in our cohorts, but the molecular mechanisms underlying this association are not yet clear. The results of knockdown and forced-expression experiments using sarcoma cell lines suggest that AFAP1L1 is involved in the process of invasion. Increased invasion of the matrix gel was confirmed in AFAP1L1-introduced ihMSC clones in association with an increase in excretion of MMP-9, a common feature of highly invasive malignant cells. We searched the ONCOMINE cancer array database (http://www.oncomine.org) and found a moderate correlation (R 2 ¼ 0.6964) between AFAP1L1 and MMP-9 in glioblastomas (Sun et al., 2006) . We have no clear explanation of why we failed to find a clear association between the expression level of AFAP1L1 and that of MMP-9 in clinical samples (Supplementary Figure S1 ). This may be due to the multifactorial control of MMP-9 expression (St-Pierre et al., 2004) , and factors other than MMP-9 may be involved in the role of AFAP1L1 in tumor cell invasion. In this respect, it is intriguing that although the introduction of AFAP1L1 expression caused no change in growth profiles in vitro, AFAP1L1 as a prognostic marker of sarcomas M Furu et al the formation of tumor masses was accelerated in vivo. This suggested a role for AFAP1L1 at the interface between tumor cells and environments. Although the AFAP1L1 gene was identified as a metastasis-associated gene from clinical data, we failed to find an association of metastasis with the expression of AFAP1L1 in experiments in vivo. The current experimental system using the subcutaneous inoculation of osteosarcomas cells may not be appropriate for evaluating the function of AFAP1L1.
AFAP1L1 is a paralogue of AFAP-110, which is an SH2/SH3-binding partner for Src (Flynn et al., 1993; Guappone and Flynn, 1997; Qian et al., 1998) . AFAP-110 contains several protein-binding motifs at its amino terminus and functions as an adapter protein for actin filaments (Qian et al., 2000; Baisden et al., 2001b; Qian et al., 2004) . It is also required to control protein kinase Ca-mediated activation of c-Src and the subsequent formation of podosomes . AFAP1L2, also known as XB130, is another paralogue of AFAP-110. AFAP1L2 associates with Src as well (Xu et al., 2007) and is predominantly expressed in the thyroid (Lodyga et al., 2009 ). AFAP1L2 cooperates with RET/PTC (rearranged in transformation/papillary thyroid carcinomas), a thyroid-specific tyrosine kinase, to increase phosphorylation of AKT, suggesting a role in thyroid cancer (Lodyga et al., 2009 ). In addition, although AFAP1L2 has structural similarities to chicken AFAP-110 with which it was identified in a search of databases, it does not associate with actin filaments, suggesting a different role from that of AFAP-110 (Lodyga et al., 2009) . We have performed a series of experiments to examine the association of AFAP1L1 with actin filaments but found no definite evidence of one (data not shown). Although we speculate that AFAP1L1 acts as an adapter protein on the basis of its structural similarity to AFAP-110, AFAP1L1 functions in sarcoma cells via mechanisms distinct from those of AFAP-110, which may confer aggressive biological features.
Materials and methods

Clinical samples
Tumor samples were obtained at resection surgery in Kyoto University Hospital and preserved as described previously (Nagayama et al., 2002) . At least 90% of the viable cells in each specimen were identified as tumor cells. Primary hMSCs (hMSCs) were obtained and cultured by a method reported previously (Shibata et al., 2007) . All samples were approved for analysis by the ethics committee of the Faculty of Medicine, Kyoto University.
Cell lines HS-SY-II was kindly provided by H Sonobe (Kochi University, Japan), SYO-1 by A Kawai (Okayama University, Japan), Fuji by S Tanaka (Hokkaido University, Japan), 1273/ 99 by O Larsson (Karolinska Institute, Sweden), NMS-2 (malignant peripheral nerve sheath tumor) by A Ogose (Niigata University, Japan) and GBS1 (MFH) by H Kanda (The Cancer Institute of the Japanese Foundation for Cancer Research, Japan). ANOS, YaFuSS and an immortalized hMSC (ihMSC) line were established in our laboratory as described previously (Aoyama et al., 2004; Ishibe et al., 2005; Shima et al., 2007) Production of anti-AFAP1L1 polyclonal antibody The polyclonal antibody for AFAP1L1 was raised by immunizing rabbits with glutathione S-transferase-fused polypeptides corresponding to codon 35-113 of the human AFAP1L1 gene and purified with standard protocols using affinity columns.
Immunohistochemical and immunocytochemical analyses
Immunohistochemical experiments using paraffin-embedded specimens of soft tissue sarcomas were performed as described previously (Kohno et al., 2006) . The anti-AFAP1L1 antibody was used at a concentration of 1 mg/ml. For immunocytochemistry, cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 and blocked with 1% bovine serum albumin in PBS. Slides were incubated with the anti-AFAP1L1 antibody or an anti-Flag M2 antibody (Sigma-Aldrich) overnight and then with a corresponding Alexa Fluor-conjugated secondary antibody (Invitrogen, Carlsbad, CA, USA). When indicated, rhodamine-phalloidin (Invitrogen) was used to stain actin fibers. Nuclei were stained with 4,6-diamidino-2-phenylindole. Cells were viewed with an IX81 (OLYMPUS, Tokyo, Japan) and photographed. The scoring was performed by two researchers without information on the clinical data for each sample.
Transient AFAP1L1 expression vectors
The coding region of the AFAP1L1 gene was cloned into the pCAGGS vector (pCAG/AFAP1L1WT) tagged at the N-terminus with 3 Â Flag. Transfection of these vectors was carried out using the Amaxa electroporation system (Amaxa Biosystems, Cologne, Germany) according to the manufacturer's instructions.
Lentiviral production
The BLOCK-iT Pol II miR RNAi Expression Vector Kit (Invitrogen) was used to knock down the AFAP1L1 gene. Two oligonucleotides targeting AFAP1L1 (Hmi456004 and 456007, designated AFAP1L1 RNAi-1 and -2) and two control microRNAs that have no homology with mammalian gene sequences (designated control RNAi-1 and -2) were designed by and purchased from Invitrogen. They were annealed and ligated into the pcDNA6.2-GW/EmGFP-miR, in which microRNA expression was driven by a cytomegalovirus promoter with simultaneous expression of EmGFP. The cassette was subsequently cloned into pLenti6/V5-DEST, and cells were infected with supernatant containing microRNA lentiviruses (4.2 Â 10 6 TU/ml) using the ViraPower Lentiviral Expression System (Invitrogen). These microRNA-transduced cells were prepared without drug selection or single-cell cloning. To generate cells stably expressing AFAP1L1, its gene was cloned into pLenti6/V5-DEST by a PCR-based method (pLenti6/AFAP1L1). As a control, a b-galactosidase gene-expressing vector (pLenti6/LacZ) was used. Cells were infected with these lentiviruses and selected with blasticidin (Invitrogen) for two weeks. Several clones of pLenti6/AFAP1L1-transduced cells were isolated by limiting dilution. pLenti6/LacZtransduced control cells were used without cloning.
Western blot analyses
Western blot analyses were performed as described previously (Kohno et al., 2006) . Membranes were incubated overnight with the anti-AFAP1L1 (1:1000), anti-Flag M2 (1:4000; SigmaAldrich) or anti-b-actin (1:4000; Sigma-Aldrich) antibody.
Matrigel invasion assay
Cell suspensions (2.5 Â 10 4 ) in 0.5 ml of DMEM without fetal bovine serum were placed in the upper chambers of 8 mm control cell culture inserts (BD Biosciences, Franklin Lakes, NJ, USA) or BioCoat matrigel invasion chambers (BD Biosciences), and 0.5 ml of DMEM containing 5% fetal bovine serum was placed in each lower chamber. After incubation for 22 h at 37 1C under 5% CO 2 , cells on the upper surface of the membrane were mechanically removed. The membranes were fixed, and stained with 1% Toluidine blue. Cells were counted in five randomly chosen fields under a magnification of Â 100. Cell invasiveness was calculated by dividing the number of cells invading through the matrigel membrane by the number invading the control insert.
Cell growth assay Cells were seeded on 96-well plates at a density of 1000 per well in quadriplicate. The next day, cell viability was assessed by WST-8 using a Cell Counting Kit (DOJINDO, Kumamoto, Japan) every 24 h, according to the manufacturer's instructions.
Colony formation in soft agar Cells (1 Â 10 4 ) were suspended in DMEM containing 0.35% agarose and layered on a solidified 0.7% agarose layer in 60-mm tissue culture plates and cultured at 37 1C under 5% CO 2 . After 4 weeks of incubation, p-iodonitrotetrazolium violet (Sigma-Aldrich) was added to count viable colonies.
Gelatin zymography
Gelatinolytic activity of the supernatant was analyzed as described elsewhere. Briefly, cells (4 Â 10 5 ) were incubated with DMEM containing 10% fetal bovine serum for 24 h and then the medium was replaced with 0.5 ml of OptiMEM1 (Invitrogen) containing 0.1% bovine serum albumin. After 16 h of incubation, the conditioned medium was analyzed on a 10% Tris-glycine gel containing 0.1% gelatin. The gel was treated with renaturating buffer for 30 min and with developing buffer for 12 h at 37 1C. Bands of gelatinolytic activity were visualized after staining the gels with 0.1% coomassie brilliant blue R-250 (Thermo Fisher Scientific Inc.) and then destaining. The digested bands were scanned by ChemiDocXRS (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Enzyme-linked immunosorbent assay
The expression of MMP-9 was quantified using a commercially available enzyme-linked immunosorbent assay system (Amersham matrix metalloproteinase-9 human biotrak ELISA system, GE Healthcare, Little Chalfont, UK) according to the manufacturer's instructions.
Animal experiments
All experiments with animals were approved by the Animal Research Committee (Graduate School of Medicine, Kyoto University) and conducted according to the Guidelines for Animal Experiments of Kyoto University. Cells (5 Â 10 6 ) suspended in 100 ml of PBS were injected subcutaneously into the hind flank region of female non-obese diabetic/Shi-scid Jic (non-obese diabetic/severe combined immunodeficient) mice at 5 weeks of age (Clea Japan, Tokyo, Japan). Tumor volumes were calculated using the formula: (length Â width Â height Â 3.14)/6.
Reverse transcription and real-time qPCR RNA extraction and reverse transcription were performed as described previously (Kohno et al., 2006) . Real-time qPCR analyses were performed with the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA). Taqman probes for AFAP1L1 (5 0 -GGCCCTTCCTCTGGGA CCCGGC-3 0 ) and AFAP-110 (Taqman Gene Expression Assays Hs00222181_m1) were purchased from Applied Biosystems. 18S rRNA was also purchased from Applied Biosystems and used as an endogenous reference. Information on primers is available upon request.
Statistical analyses
Statistical analyses were performed using StatView software (SAS Institute Inc., Cary, NC, USA). Univariate and multivariate analyses were performed using Cox's proportional hazards model. The statistical significance of Kaplan-Meier curves was assessed by log-rank (Mantel-Cox) test. For comparisons of two individual data points, a two-sided Student's t-test was applied to assess statistical significance. An analysis of variance with post hoc testing was used for comparisons of more than three.
